相似文献
1
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.用P-糖蛋白阻滞剂SDZ PSC 833处理的小鼠中紫杉醇口服生物利用度提高。
Br J Cancer. 1997;76(9):1181-3. doi: 10.1038/bjc.1997.530.
2
Oral delivery of taxanes.紫杉烷类的口服给药
Invest New Drugs. 2001 May;19(2):155-62. doi: 10.1023/a:1010635000879.
3
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.通过联合给予P-糖蛋白抑制剂KR30031提高紫杉醇的口服生物利用度。
Pharm Res. 2003 Jan;20(1):24-30. doi: 10.1023/a:1022286422439.
4
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.P-糖蛋白和细胞色素 P450 3A 共同作用限制紫杉醇的口服生物利用度。
Int J Cancer. 2013 May 15;132(10):2439-47. doi: 10.1002/ijc.27912. Epub 2012 Nov 14.
5
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.多药耐药逆转剂MS-209对P-糖蛋白的抑制作用增强了口服紫杉醇的生物利用度和抗肿瘤疗效。
Cancer Chemother Pharmacol. 2002 Apr;49(4):322-8. doi: 10.1007/s00280-001-0419-x. Epub 2002 Feb 1.
6
Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.在一种新型自微乳化药物递送系统中，无论是否同时使用P-糖蛋白抑制剂，紫杉醇的口服吸收均得到增强。
Pharm Res. 2004 Feb;21(2):261-70. doi: 10.1023/b:pham.0000016238.44452.f1.
7
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.维拉帕米对游离紫杉醇药代动力学的影响。
Invest New Drugs. 2003 Aug;21(3):291-8. doi: 10.1023/a:1025412509730.
8
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.P-糖蛋白拮抗剂PSC 833的初始药代动力学和生物利用度
J Clin Pharmacol. 1997 Feb;37(2):123-8. doi: 10.1002/j.1552-4604.1997.tb04770.x.
9
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.紫杉醇自微乳化制剂：小鼠口服生物利用度研究
Invest New Drugs. 2010 Apr 13;29(5):768-76. doi: 10.1007/s10637-010-9421-7. Print 2011 Oct.
10
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.环孢素A联合处理的小鼠中紫杉醇口服吸收增强且消除减少。
Clin Cancer Res. 1998 Oct;4(10):2293-7.
引用本文的文献
1
Semi-automated, high-content imaging of drug transporter knockout sea urchin (Lytechinus pictus) embryos.全自动、高通量药物转运蛋白敲除海胆（Lytechinus pictus）胚胎的高内涵成像。
J Exp Zool B Mol Dev Evol. 2024 May;342(3):313-329. doi: 10.1002/jez.b.23231. Epub 2023 Dec 12.
2
Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel.发现黄酮类化合物FM04作为一种强效抑制剂，可逆转异种移植中P-糖蛋白介导的耐药性并提高紫杉醇的口服生物利用度。
Int J Mol Sci. 2022 Dec 4;23(23):15299. doi: 10.3390/ijms232315299.
3
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability.具有P-糖蛋白抑制作用的药物制剂作为增强口服药物吸收和生物利用度的有前景方法。
Pharmaceutics. 2021 Jul 20;13(7):1103. doi: 10.3390/pharmaceutics13071103.
4
A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.A2A 腺苷受体调节血脑屏障处的药物外排转运体 P-糖蛋白。
J Clin Invest. 2016 May 2;126(5):1717-33. doi: 10.1172/JCI76207. Epub 2016 Apr 4.
5
Role of pregnane X receptor in chemotherapeutic treatment. pregnane X 受体在化疗治疗中的作用。
Cancer Chemother Pharmacol. 2014 Aug;74(2):217-27. doi: 10.1007/s00280-014-2494-9. Epub 2014 Jun 3.
6
Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats.芹菜素、芦丁与紫杉醇在大鼠体内由P-糖蛋白介导的药代动力学药物相互作用。
Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):267-76. doi: 10.1007/s13318-014-0203-z. Epub 2014 May 29.
7
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.联合口服依利格鲁司他和利托那韦可提高口服紫杉醇和多西他赛的血浆水平，而不影响相对脑内蓄积。
Br J Cancer. 2014 May 27;110(11):2669-76. doi: 10.1038/bjc.2014.222. Epub 2014 Apr 29.
8
Polymers influencing transportability profile of drug.聚合物影响药物的可传递性特征。
Saudi Pharm J. 2013 Oct;21(4):327-35. doi: 10.1016/j.jsps.2012.10.003.
9
P-glycoprotein Inhibition for Optimal Drug Delivery.P-糖蛋白抑制作用以实现最佳药物递送。
Drug Target Insights. 2013 Aug 19;7:27-34. doi: 10.4137/DTI.S12519.
10
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.口服抗癌药物：低生物利用度的机制与改善策略。
Clin Pharmacokinet. 2013 Jun;52(6):399-414. doi: 10.1007/s40262-013-0040-2.
本文引用的文献
1
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.紫杉醇（泰素）在肠道中因P-糖蛋白导致口服生物利用度有限及活跃的上皮排泄。
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5. doi: 10.1073/pnas.94.5.2031.
2
Pharmacological considerations in the modulation of multidrug resistance.多药耐药性调控中的药理学考量
Eur J Cancer. 1996 Jun;32A(6):1082-8. doi: 10.1016/0959-8049(96)00111-6.
3
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.紫杉醇在小鼠体内的非线性药代动力学是由药用辅料聚氧乙烯蓖麻油引起的。
Cancer Res. 1996 May 1;56(9):2112-5.
4
Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.人细胞色素P450 3A4：含NADPH-P450还原酶的纯化重组融合蛋白的酶学性质
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11748-52. doi: 10.1073/pnas.90.24.11748.
5
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.紫杉醇在CD2F1小鼠体内的血浆药代动力学和组织分布
Cancer Chemother Pharmacol. 1994;34(6):465-71. doi: 10.1007/BF00685656.
6
7
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.小鼠多药耐药蛋白1a（mdr1a）P-糖蛋白基因的破坏导致血脑屏障缺陷，并增加对药物的敏感性。
Cell. 1994 May 20;77(4):491-502. doi: 10.1016/0092-8674(94)90212-7.
8
[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level].紫杉醇在实验动物中的药代动力学。第1部分。血药浓度
Gan To Kagaku Ryoho. 1994 Apr;21(5):653-8.
9
Paclitaxel (taxol).紫杉醇（泰素）。
N Engl J Med. 1995 Apr 13;332(15):1004-14. doi: 10.1056/NEJM199504133321507.
10
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.采用半自动反相高效液相色谱法测定小鼠血浆、组织、尿液和粪便中的紫杉醇及其代谢物。
J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):383-91. doi: 10.1016/0378-4347(94)00495-q.
Zotero 插件